Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Pre-Tax Margin
Income before tax as a percentage of revenue.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Pre-Tax Margin · Q4 FY2025 · quarter ended Dec 2025
Pre-tax margin at -75.8%
Pre-tax margin was -75.8% in Q4 FY2025. Over 3 fiscal years it narrowed by 86.3 pp.
Context
- Pre-tax margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -61.8%
- Year-over-year change
- -69.5pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -61.8% | -69.5pp |
| FY2024 | 2024-12-31 | 7.7% | -13.0pp |
| FY2023 | 2023-12-31 | 20.7% | -3.9pp |
| FY2022 | 2022-12-31 | 24.6% | -0.2pp |
| FY2021 | 2021-12-31 | 24.8% | — |
Pre-Tax Margin vs competitors
How ZYBT compares with its peers on the latest reported figures
- ZYBT's FY2025 pre-tax margin of -61.8% is the 3rd highest of the 5 companies compared; the peer median is -2293.4%.
- Its year-over-year change of -69.5 pp is the 3rd highest of 5, against a peer median of -1933.4 pp.
- Over three fiscal years its change of -86.3 pp compares with a peer median of -3334.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 21.6% | +2.2 pp | +4.6 pp | |
| LTM Mar 2026 | -15.6% | +26.5 pp | +31.0 pp | |
| FY2025 | -61.8% | -69.5 pp | -86.3 pp | |
| LTM Mar 2026 | -4571.1% | -3869.1 pp | -6672.7 pp | |
| LTM Mar 2026 | -56386.0% | -27700.7 pp | -22930.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
EXOZeXoZymes, Inc. | FY2025 | — | — | — |
| Peer median (excluding ZYBT) | -2293.4% | -1933.4 pp | -3334.1 pp | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 214.07M | 260.27M | 211.65M | 186.36M | 116.36M |
| Cost of Revenue | 88.67M | 106.75M | 81.8M | 95.06M | 92.49M |
| Gross Profit | 125.39M | 153.52M | 129.86M | 91.3M | 23.87M |
| Gross Margin | 58.6% | 59.0% | 61.4% | 49.0% | 20.5% |
| Research & Development | 11.37M | 13.42M | 11.9M | 12.79M | 18.01M |
| Selling, General & Admin | 58.19M | 63.56M | 66.63M | 63.84M | 74.92M |
| Operating Expenses | 73.01M | 87.69M | 84.87M | 74.86M | 92.12M |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| EBITDA | 70.12M | 85.55M | 72.1M | 42.6M | (42.52M) |
| EBITDA Margin | 32.8% | 32.9% | 34.1% | 22.9% | -36.5% |
| Operating Income | 52.38M | 65.83M | 44.99M | 16.44M | (68.25M) |
| Operating Margin | 24.5% | 25.3% | 21.3% | 8.8% | -58.7% |
| Interest Income | 112K | 114K | 312K | 231K | 96K |
| Interest Expense | 1.05M | 2.84M | 4.42M | 4.04M | 3.4M |
| Other Income / Expenses | 683K | (1.92M) | (1.22M) | (2.05M) | (3.62M) |
| Income Before Tax | 53.07M | 63.91M | 43.76M | 14.39M | (71.87M) |
| Pre-Tax Margin | 24.8% | 24.6% | 20.7% | 7.7% | -61.8% |
| Income Tax Expense | 6.6M | 8.17M | 6.25M | 924K | 11.1M |
| Net Income | 38.96M | 46.74M | 31.46M | 11.31M | (69.78M) |
| Net Margin | 18.2% | 18.0% | 14.9% | 6.1% | -60.0% |
| EPS (Basic) | 0.85 | 1.02 | 0.69 | 0.24 | (1.40) |
| EPS (Diluted) | 0.83 | 0.99 | 0.67 | 0.24 | (1.40) |
| Weighted Avg Shares | 45.67M | 45.67M | 45.67M | 47.17M | 47.35M |
| Weighted Avg Shares (Diluted) | 47.17M | 47.17M | 47.17M | 47.17M | 47.35M |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.